SCHEMBL30909080

SCHEMBL30909080

CN1CCC(c2coc3ccc(NC(=O)c4c(F)cc(F)cc4F)nc23)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR1F P30939 19/20 1.00
HTR1D P28221 11/20 0.56
HTR1E P28566 2/20 0.56
CHRM5 P08912 1/20 0.56
DRD5 P21918 1/20 0.56
HTR7 P34969 1/20 0.56
OPRK1 P41145 1/20 0.56
TMEM97 Q5BJF2 1/20 0.56
SIGMAR1 Q99720 1/20 0.56
HTR1A P08908 12/20 0.52
HTR1B P28222 11/20 0.52
HTR2A P28223 2/20 0.52
HTR2C P28335 2/20 0.52
HTR2B P41595 1/20 0.52
HTR4 Q13639 1/20 0.51
PIM1 P11309 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30909202 0.87 HTR1F (1.00) HTR1FHTR1DHTR1EHTR1AHTR1B
SCHEMBL30909192 0.86 HTR1F (1.00) HTR1FHTR1DHTR1ECHRM5DRD5
SCHEMBL30909022 0.84 HTR1F (1.00) HTR1FHTR1DHTR1EHTR1AHTR1B
SCHEMBL12021094 0.73 HTR1F (0.72) HTR1FHTR1DHTR1ECHRM5DRD5
SCHEMBL4503014 0.73 HTR1F (0.68) HTR1FHTR1DHTR1ECHRM5DRD5
SCHEMBL7011605 0.72 HTR1F (0.81) HTR1FHTR1DHTR1EHTR1AHTR1B
Lasmiditan SCHEMBL536057 0.72 HTR1F (1.00) HTR1FHTR1DHTR1ECHRM5DRD5
Lasmiditan SCHEMBL29376817 0.72 HTR1F (1.00) HTR1FHTR1DHTR1ECHRM5DRD5
Hydrochloric Acid SCHEMBL1198211 0.72 HTR1F (0.70) HTR1FHTR1DHTR1ECHRM5DRD5
Hydrochloric Acid SCHEMBL4493509 0.72 HTR1F (0.67) HTR1FHTR1DHTR1ECHRM5DRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
WO-2024073845-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ, LIMITED PARTNERSHIP (CA) 2024-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D HTR1F 1/4885HTR1D 3/4885HTR1E 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.